PharmaShots Weekly Snapshots (January 03

ObsEva Reports Results of Linzagolix in P-III (EDELWEISS 3) Trial for the Treatment of Endometriosis-Associated Pain

Published: Jan 07, 2022 | Tags: ObsEva, Linzagolix, P-III, EDELWEISS 3 Trial, Endometriosis-Associated Pain

AstraZeneca Entered into an Exclusive Licence Agreement with Neurimmune to Develop and Commercialize NI006 for ATTR-CM

Published: Jan 07, 2022 | Tags: AstraZeneca, Neurimmune, NI006, ATTR-CM

Exscientia Entered into a Research Collaboration with Sanofi to Develop Cancer & Immunology Therapies

Published: Jan 07, 2022 | Tags: Exscientia, Sanofi, Cancer, Immunology

Lilly Entered into a Research and Collaboration Agreement with Entos to Develop Nucleic Acid-Based Therapies in Multiple Neurologic Indications

Published: Jan 07, 2022 | Tags: Lilly, Entos, Nucleic Acid Therapies, Neurologic

Stryker Signs a Definitive Agreement to Acquire Vocera Communications for ~$3.09B

Published: Jan 07, 2022 | Tags: Stryker, Vocera Communications, ~$3.09B

Amgen Entered into a Research Collaboration Agreement with Generate Biomedicines to Discover Protein Therapeutics

Published: Jan 07, 2022 | Tags: Amgen, Generate Biomedicines, Protein Therapeutics

Junshi Entered into a Collaboration with DotBio to Develop Cancer Therapies

Published: Jan 06, 2022 | Tags: Junshi, DotBio, Cancer, DotBody modules

Exelixis Reports Completion of Patient Enrollment in P-III (CONTACT-03) Trial of Cabometyx (cabozantinib) + atezolizumab for Metastatic RCC

Published: Jan 06, 2022 | Tags: Exelixis, P-III, CONTACT-03 Trial, Cabometyx, cabozantinib, atezolizumab, Metastatic RCC

BeiGene’s Tislelizumab Receives NMPA’s Approval as 2L & 3L Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

Published: Jan 06, 2022 | Tags: BeiGene, Tislelizumab, NMPA, Approval, Non-Small Cell Lung Cancer

Jazz Publishes Results of Xywav in P-III Study for the Treatment of Idiopathic Hypersomnia in Lancet Neurology

Published: Jan 06, 2022 | Tags: Jazz, Xywav, P-III, Study, Idiopathic Hypersomnia, Lancet Neurology

NiKang Entered into a Clinical Trial Collaboration with AVEO to Evaluate NKT2152 and Fotivda (tivozanib) for Advanced Clear Cell Renal Cell Carcinoma

Published: Jan 06, 2022 | Tags: NiKang, AVEO, NKT2152, Fotivda, tivozanib, Advanced Clear Cell Renal Cell Carcinoma

Intellia Entered into a License Agreement with Kyverna to Develop KYV-201 for the Treatment of Autoimmune Diseases

Published: Jan 06, 2022 | Tags: Intellia, Kyverna, KYV-201, Autoimmune Diseases

Amryt Publishes Results of Mycapssa in P-III (MPOWERED) Trial for the Treatment of Acromegaly in The Lancet Diabetes & Endocrinology

Published: Jan 05, 2022 | Tags: Amryt, Mycapssa, P-III, MPOWERED Trial, Acromegaly, Lancet, Diabetes, Endocrinology

Amylyx Reports Submission of MAA to EMA for AMX0035 to Treat ALS

Published: Jan 05, 2022 | Tags: Amylyx, MAA, EMA, AMX0035, ALS

AbbVie’s Telisotuzumab Vedotin (Teliso-V) Receives the US FDA’s Breakthrough Therapy Designation for Non-Small Cell Lung Cancer

Published: Jan 05, 2022 | Tags: AbbVie, Telisotuzumab Vedotin, Teliso-V, US, FDA, Breakthrough Therapy Designation, Non-Small Cell Lung Cancer

Biogen Exercises its Option with Ionis to Develop and Commercialize BIIB115/ION306 for the Treatment of SMA

Published: Jan 05, 2022 | Tags: Biogen, Ionis, BIIB115, ION306, SMA

AVEO Entered into a Clinical Trial Collaboration with Merck KGaA to Evaluate Ficlatuzumab and Erbitux (cetuximab) for Recurrent or Metastatic HNSCC

Published: Jan 05, 2022 | Tags: AVEO, Merck KGaA, Ficlatuzumab, Erbitux, cetuximab, Recurrent, Metastatic, HNSCC

Genmab Signs a License Agreement with Synaffix for ADC Technology to Treat Cancer

Published: Jan 05, 2022 | Tags: Genmab, Synaffix, ADC, Technology, Cancer

Hansa Biopharma Signs an Agreement with AskBio to Evaluate Imlifidase as Pre-Treatment in Pompe Disease

Published: Jan 04, 2022 | Tags: Hansa Biopharma, AskBio, Imlifidase, Pompe Disease

Allarity Signs a License Agreement with Oncoheroes Biosciences to Advance Dovitinib and Stenoparib for Pediatric Cancer

Published: Jan 04, 2022 | Tags: Allarity, Oncoheroes Biosciences, Dovitinib, Stenoparib, Pediatric Cancer

UNION Reports First Patient Enrollment in P-IIb (IASOS) Study of Orismilast for the Treatment of Psoriasis

Published: Jan 04, 2022 | Tags: UNION, P-IIb, IASOS Study, Orismilast, Psoriasis

Santhera Collaborates with Sperogenix to Develop and Commercialize Vamorolone for Rare Diseases in the Greater China

Published: Jan 04, 2022 | Tags: Santhera, Sperogenix, Vamorolone, Rare Diseases, Greater China, DMD, US, EU

Asieris Reports World’s First Patient Dosing in P-I/II Study of Combination Regimen as a Neoadjuvant Therapy for MIBC Patients

Published: Jan 04, 2022 | Tags: Asieris, Neoadjuvant Therapy, MIBC, Patients, APL-1202, BeiGene, tislelizumab

Pfizer and BioṆTech’ s Booster Receive the US FDA’s EUA for Adolescents

Published: Jan 04, 2022 | Tags: Pfizer, BioṆTech, Booster, COVID-19, US, FDA, EUA, Adolescents

Ovid Therapeutics Entered into an Exclusive License Agreement with AstraZeneca to Expand its Epilepsy Franchise with Novel KCC2 Activators

Published: Jan 03, 2022 | Tags: Ovid Therapeutics, AstraZeneca, OV329, Pregabalin, Tuberous sclerosis, Soticlestat, Dravet, Lennox Gastaut Syndromes

Bionomics Initiates P-II (PREVAIL) Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

Published: Jan 03, 2022 | Tags: Bionomics, BNC210, Social Anxiety Disorder, US FDA, US IRB, PTSD

Cantargia Plans to Evaluate Nadunolimab Against Metastatic Pancreatic Cancer

Published: Jan 03, 2022 | Tags: Cantargia, Nadunolimab, Metastatic Pancreatic Cancer, US, FDA,

Novavax Submits Final Data to Seek the US FDA’s EUA for its COVID-19 Vaccine

Published: Jan 03, 2022 | Tags: Novavax, US, FDA, EUA, COVID-19, Vaccine, NVX-CoV2373, Matrix-M

Kintor Pharma Reports First Patient Dosing in P-III Study of KX-826 (pyrilutamide) for Androgenic Alopecia in China

Published: Jan 03, 2022 | Tags: Kintor Pharma, P-III, Study, KX-826, pyrilutamide, Androgenic Alopecia, China